Monitoring different genetic types of T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is looking at people with peripheral T-cell lymphoma, a type of blood cancer. It will use genetic testing to understand different subtypes of the cancer and how they affect patients' outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with peripheral T-cell lymphoma (a certain type of blood cancer).
- You need to have had or be willing to have a genetic test (NGS) to look at the tumor's DNA.
- You must agree to sign a consent form and follow the study's procedures, including long-term follow-up.
- If you are female and able to have children, you must use effective birth control or not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how peripheral T-cell lymphoma (PTCL) behaves and responds to treatment in real-world settings. It includes patients diagnosed over many years to better understand the disease and improve care.
This study, run by Massachusetts General Hospital, is collecting information from people around the world who have certain types of T-cell or NK-cell lymphoma. It aims to learn more about these cancers and how they are managed.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This trial uses a genetic test on your lymphoma tissue to help choose your treatment. It may help personalize therapy for people with newly diagnosed peripheral T-cell lymphoma and see how well the approach works and is tolerated.
This study is testing whether a treatment chosen based on your tumor's genetic makeup works better than a standard one for people newly diagnosed with peripheral T-cell lymphoma. The goal is to find a more personalized approach that targets your specific cancer.
This is an observational registry that collects real-world information about people newly diagnosed with peripheral T-cell or certain NK-cell lymphomas. It does not test a new drug, but it helps researchers understand patterns of disease and care, which can guide future studies.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.